Abstract:Background: Demographic diversity among clinical trials is required for representing the real-world populations intended for treatment and disease prevention. Moreover, genetic and environmental differences between ethnic and racial groups necessitate appropriately powered trials for relevant subgroups. We investigate the racial and ethnic demographic diversity of US-based participants in GSK-sponsored interventional trials. We also assess the evaluation of demographic diversity against US Census and epidemiologic data. Methods: GSK-sponsored interventional phase I-IV clinical trials conducted from 2002 to 2019 across three areas were analyzed: pharmaceutical (includes therapeutic medicines except for vaccines and human immunodeficiency virus (HIV)), vaccine (includes prophylactic and therapeutic vaccines), and ViiV (includes HIV therapies). A total of 1005 global trials encompassing 460,707 global participants were identified, of which 495 had US-based sites with a total of 108,261 (23.5% of global) US participants (pharmaceutical, n = 357 trials; vaccine, n = 45 trials; and ViiV, n = 93 trials). We evaluated how GSK US-based trial recruitment compares with US Census (in line with previously published studies from other groups) and with epidemiologic data. Results: GSK participant data for race and ethnicity combined across areas were generally similar to US Census levels (e.g. GSK versus census: White, 76.5% versus 76.3%; Black or African American, 15.1% versus 13.4%; Asian, 1.8% versus 5.9%; Hispanic or Latino, 14.0% versus 18.5%; Non-Hispanic White, 63.5% versus 60.1%). However, this was not the case for the individual pharmaceutical, vaccine, and ViiV data sets; least represented groups were Asian individuals for pharmaceutical and ViiV trials and American Indian or Alaskan Native individuals for vaccine trials (6.2%, 11.8%, and 11.1% of trials met/exceeded census level representation, respectively). The percentage of trials reaching/exceeding census levels also varied per trial phase for race and ethnicity. Furthermore, disparities in the percentage of trials reaching/exceeding census levels versus epidemiology-based prevalence levels have revealed opportunities to improve industry success metrics; in HIV trials, the proportion of Black or African American individuals (35.1%) exceeded census (13.4%) but not epidemiologic levels (55.3%). Conclusion: Further work is required to achieve demographic diversity across clinical trials. We conclude that US Census data are an inappropriate universal benchmark. A shift to epidemiology benchmarking will enable the consideration of global participants into US analyses for highly intrinsic (i.e. influenced by ancestry) diseases and more firm requirements for US-based participants into US analyses for extrinsic (i.e. influenced by location or culture) diseases. Benchmarking in line with epidemiologic data will allow us to set better trial enrollment goals, with the aim of conducting more demographically balanced, diverse, and representative clinical trials and enabling a better understanding of drug safety and efficacy per demographic group.

Diversity in pulmonary rehabilitation clinical trials: a systematic review of the literature

A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers

Racial and ethnic representation in peripheral artery disease randomized clinical trials

Diversity in randomized clinical trials for peripheral artery disease: a systematic review

Exploring Demographic Representation and Reporting in Lung Cancer Clinical Trials with Canadian Sites from 2013 to 2023

Participation in Non-small Cell Lung Cancer Clinical Trials in the United States by Race/Ethnicity

A comprehensive analysis of patient demographics and disparities in contemporary oncology clinical trials (2022-2023).

Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel

Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

Abstract HUP12: Underrepresentation Of Racial And Ethnic Minorities In Stroke Clinical Trials

Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials

Disparities in clinical trial participation: Survey of patients with cancer at an academic medical center.

Abstract WMP58: Underrepresentation of Racial and Ethnic Minorities in Stroke Clinical Trials

Pulmonary Rehabilitation in the Management of Chronic Obstructive Pulmonary Disease among Asian Indians- Current Status and Moving Forward

Gender, race, and ethnicity in lung cancer clinical trial participation: Analysis of 253,845 patients from 2002 to 2021

Unveiling inequities in representation: Racial disparities in supportive care breast cancer clinical trial enrollment.

Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis

Enrollment of underserved racial and ethnic populations in pediatric asthma clinical trials

(198) Gaps in Patient Representation for Peyronie’s Disease Clinical Trials

578 A Cross-Sectional Study of Sex, Race, and Ethnic Representation in Burn Clinical Trials

Recruitment, retention and reporting of variables related to ethnic diversity in randomised controlled trials: an umbrella review